Dapagliflozin Tablet, Film Coated
Product Images NDC 63629-3253

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 63629-3253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
FDA Label Image

Figure_1 (Farxiga Fig1)

Figure_1 (Farxiga Fig1)
FDA Label Image

Figure_10a (Figure 10a)

Figure_10a (Figure 10a)
FDA Label Image

Figure_10b (Figure 10b)

Figure_10b (Figure 10b)
FDA Label Image

Figure_11 (Figure 11 01)

Figure_11 (Figure 11 01)
Not available*
FDA Label Image

Figure_8b (Figure 8b)

Figure_8b (Figure 8b)
Not available.*
FDA Label Image

Figure-9b (Figure 9b 01)

Figure-9b (Figure 9b 01)
FDA Label Image

Figure_2 (Image 01)

Figure_2 (Image 01)
Not available*
FDA Label Image

Figure_3 (Image 02)

Figure_3 (Image 02)
Not available.*
FDA Label Image

Figure_6 (Image 03)

Figure_6 (Image 03)
This text provides information about a clinical study involving a drug called Dapagliflozin. The study compares the effectiveness of Dapagliflozin versus a placebo in a group of patients. The results show that patients taking Dapagliflozin had a lower incidence of an unspecified event compared to those taking the placebo. The Hazard Ratio (HR) is reported as 0.61 with a 95% confidence interval (CI) of 0.51 to 0.72. The p-value is noted as less than 0.0001, indicating a statistically significant difference between the two groups. The text also includes a chart showing the number of patients at risk over a span of 32 months from randomization.*
FDA Label Image

Figure_7a (Image 04)

Figure_7a (Image 04)
This text contains information about patients who were given Dapagliflozin compared to placebo in a clinical trial. The number of patients with an event (%), the hazard ratio with a confidence interval, and the p-value are reported. Additionally, the number of patients at risk at different time points from randomization is provided.*
FDA Label Image

Figure-7b (Image 05)

Figure-7b (Image 05)
Not available.*
FDA Label Image

Figure-8a (Image 06)

Figure-8a (Image 06)
The text provides information about a comparison between Dapagliflozin and Placebo for treating patients, with data shown in terms of months from randomization and the number of patients at risk. The result suggests that Dapagliflozin may have a significant effect compared to Placebo, with a hazard ratio of 0.82 and a p-value of 0.0294.*
FDA Label Image

Figure-9a (Image 07)

Figure-9a (Image 07)
FDA Label Image

Label (Lbl636293253)

Label (Lbl636293253)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.